Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Study: New combination therapy to treat chronic hepatitis C

Study: New combination therapy to treat chronic hepatitis C

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

New drug combination proves effective in treating patients with HCV genotype 1

New drug combination proves effective in treating patients with HCV genotype 1

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

New research provides new hope for liver transplant patients with recurring hepatitis C

New research provides new hope for liver transplant patients with recurring hepatitis C

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Medivir announces phase III ATTAIN study of simeprevir inhibitor in treatment of adult patients with HCV

Experimental drugs offer hope for people with hepatitis C

Experimental drugs offer hope for people with hepatitis C

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Study findings suggest potential targets for treating HCV

Study findings suggest potential targets for treating HCV

Gilead submits NDA  to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Daclatasvir–sofosbuvir combo effective in chronic HCV infection

Daclatasvir–sofosbuvir combo effective in chronic HCV infection

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6% to $4.4 billion